The selective AKT1,2,3 inhibitor capivasertib (AZD5363)27 has shown statistically significant and clinically meaningful improvement in PFS in the Phase III trial CAPItello-291 in ER+BC when combined with fulvestrant28. This evidence concerns the gene AKT1 and breast cancer.